NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

February 22, 2021

Study Completion Date

May 19, 2021

Conditions

Pre DiabetesPolycystic Ovary SyndromeObesity Android

Interventions

DRUG

Liraglutide Pen Injector [Saxenda]

daily sc injection of liraglutide with final dose of 3mg daily

DRUG

Placebo Liraglutide Pen Injector

daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo

Trial Locations (1)

Woman's Hospital, Baton Rouge